e-SPACE Heart Failure 2021

Published: 07 December 2021

Views:
5684
Likes:
7

Views:
5684
Likes:
7
Share:

Now Playing
Part 1 | Session 3 of 9
The new HF guidelines: diagnostic & treatment algorithms
Justin Ezekowitz, Yury Lopatin, Marco Metra

Up Next
1h 5m 20s

Part 1 | Session 4 State of the art management of chronic HF
44m 49s

Part 1 | Session 5 Satellite symposium – Tailoring treatment to optimise care in HFrEF: The role of SGLT2 inhibitors (A symposium sponsored by the Boehringer Ingelheim & Lilly Alliance)
1h 5m 53s

Part 1 | Session 6 Acute HF and the transition to ambulatory care
1h 4m 2s

Part 1 | Session 7 Update on advanced HF, assist devices and heart transplantation
21m 56s

Part 1 | Session 8 Satellite symposium – Neuromodulation for the management of patients with HFrEF: the present and the future (Supported by an educational grant from CVRx)
1h 6m 7s

Part 1 | Session 9 Difficult problems in HF

1h 7m 48s

Part 2 | Session 1 Co-morbidities in HF affecting QoL and hard outcomes (part 1)
45m 28s

Part 2 | Session 2 Meet-the-expert session – Balancing RAASi therapy and potassium (Supported by an educational grant funding from AstraZeneca)
1h 9m 18s

Part 2 | Session 3 Co-morbidities in HF affecting QoL and hard outcomes (part 2)
1h 6m

Part 2 | Session 4 Valvular heart disease in HF
42m 18s

Part 2 | Session 5 Satellite symposium – Management of heart failure with PRESERVED ejection fraction ‒ time to tackle the unmet need (A symposium organised by Charite Friends & Sponsors Trust, supported by the Boehringer Ingelheim & Lilly Alliance)
1h 4m 1s

Part 2 | Session 6 Real-world data, Covid-19 & biomarkers
1h 4m 13s

Part 2 | Session 7 The new HF guidelines: diagnostic & treatment algorithms
44m 53s

Part 2 | Session 8 Meet-the-expert session – Symptoms, function and quality of life In patients with HFpEF (Supported by an educational grant funding from AstraZeneca)
1h 5m 26s

Part 2 | Session 9 State of the art management of chronic HF

1h 7m 20s

Part 3 | Session 1 Acute HF and the transition to ambulatory care
36m 34s

Part 3 | Session 2 Meet-the-expert session – GUIDE-HF: main findings and implications in clinical practice (Supported by an unrestricted educational grant by Abbott)
1h 5m 20s

Part 3 | Session 3 Update on advanced HF, assist devices and heart transplantation
1h 4m 54s

Part 3 | Session 4 Difficult problems in HF
45m 38s

Part 3 | Session 5 Satellite symposium – Implementing heart failure guidelines – management of iron deficiency along the patient’s journey (Supported by an unrestricted educational grant from Vifor Pharma)
1h 6m 4s

Part 3 | Session 6 Co-morbidities in HF affecting QoL and hard outcomes (part 1)
52m 48s

Part 3 | Session 7 Co-morbidities in HF affecting QoL and hard outcomes (part 2)
52m 48s

Part 3 | Session 8 The need for global cascade guidelines: Key points in the HF guideline approach
58m 45s

Part 3 | Session 9 Valvular heart disease in HF

1h 3m 5s

Part 1 | Session 1 Real-world data, Covid-19 & biomarkers Lars H Lund, James L Januzzi

45m 19s

Part 1 | Session 2 Meet-the-expert session – Patient profiling in HF: tailoring medical therapy (Supported by an educational grant funding from AstraZeneca)

Average (ratings)

No ratings

Your rating

Overview

e-SPACE Heart Failure 2021 was the second edition of the annual global online conference on heart failure. Brining together leading experts from across the globe, the sessions were designed to provide insight and best demonstrate how leading experts are implementing the new heart failure guidelines into clinical practice. Discover the latest information on diagnosis and evidence-based management strategies from across the globe.

Heart failure is a major public health problem facing millions of patients worldwide. It represents an ever-increasing burden for healthcare systems, patients and healthcare professionals. Care for heart failure patients requires constant education and up-to-date information. The health outcomes of heart failure patients depend upon the implementation of best care approaches and evidence-based management strategies. e-SPACE Heart Failure 2021 strives to share the latest scientific information with the global medical community.

These on-demand recordings of the live virtual event (8 – 10 October 2021) comprise:

Expert opinion and discussions from +40 international heart failure experts
+10 sessions covering the latest HF scientific information and education
Meet the Expert sessions and Symposia

e-SPACE Heart Failure 2021 would like to thank the following partners:

More from this programme

Part 1

DAY 1

9 sessions
Real-world data, Covid-19 & biomarkers	Watch now
Meet-the-expert session – Patient profiling in HF: tailoring medical therapy (Supported by an educational grant funding from AstraZeneca)	Watch now
The new HF guidelines: diagnostic & treatment algorithms	Watch now
State of the art management of chronic HF	Watch now
Satellite symposium – Tailoring treatment to optimise care in HFrEF: The role of SGLT2 inhibitors (A symposium sponsored by the Boehringer Ingelheim & Lilly Alliance)	Watch now
Acute HF and the transition to ambulatory care	Watch now
Update on advanced HF, assist devices and heart transplantation	Watch now
Satellite symposium – Neuromodulation for the management of patients with HFrEF: the present and the future (Supported by an educational grant from CVRx)	Watch now
Difficult problems in HF	Watch now

Part 2

DAY 2

9 sessions
Co-morbidities in HF affecting QoL and hard outcomes (part 1)	Watch now
Meet-the-expert session – Balancing RAASi therapy and potassium (Supported by an educational grant funding from AstraZeneca)	Watch now
Co-morbidities in HF affecting QoL and hard outcomes (part 2)	Watch now
Valvular heart disease in HF	Watch now
Satellite symposium – Management of heart failure with PRESERVED ejection fraction ‒ time to tackle the unmet need (A symposium organised by Charite Friends & Sponsors Trust, supported by the Boehringer Ingelheim & Lilly Alliance)	Watch now
Real-world data, Covid-19 & biomarkers	Watch now
The new HF guidelines: diagnostic & treatment algorithms	Watch now
Meet-the-expert session – Symptoms, function and quality of life In patients with HFpEF (Supported by an educational grant funding from AstraZeneca)	Watch now
State of the art management of chronic HF	Watch now

Part 3

DAY 3

9 sessions
Acute HF and the transition to ambulatory care	Watch now
Meet-the-expert session – GUIDE-HF: main findings and implications in clinical practice (Supported by an unrestricted educational grant by Abbott)	Watch now
Update on advanced HF, assist devices and heart transplantation	Watch now
Difficult problems in HF	Watch now
Satellite symposium – Implementing heart failure guidelines – management of iron deficiency along the patient’s journey (Supported by an unrestricted educational grant from Vifor Pharma)	Watch now
Co-morbidities in HF affecting QoL and hard outcomes (part 1)	Watch now
Co-morbidities in HF affecting QoL and hard outcomes (part 2)	Watch now
The need for global cascade guidelines: Key points in the HF guideline approach	Watch now
Valvular heart disease in HF	Watch now

Faculty Biographies

Justin Ezekowitz

Dr. Ezekowitz, an accomplished professional in the field of cardiology, serves as the co-director of the Canadian VIGOUR Centre at the University of Alberta. He has spearheaded the establishment of five new heart failure clinics across Alberta to enhance access to specialized services. Furthermore, he plays a pivotal role in co-chairing the heart failure care pathway initiative as part of Alberta Health Services Strategic Clinical Networks.

Dr. Ezekowitz's clinical focus centers on cardiology, with a primary emphasis on heart failure. He practices at the Mazankowski Alberta Heart Institute, where he contributes to the Heart Function Clinic.

In the realm of research, Dr. Ezekowitz dedicates his efforts to acute and chronic heart failure, particularly in individuals with heart "pump" issues or end-stage heart disease. He actively engages in numerous local and international clinical trials aimed at identifying novel treatments and care strategies for heart failure…

View full profile

Yury Lopatin

View full profile

Marco Metra

Professor

Marco Metra is Full Professor of Cardiology and Director of the Institute of Cardiology of the Civil Hospital and University of Brescia, Italy, and Editor-in-Chief of the European Journal of Heart Failure and Senior Consulting Editor of the European Heart Journal.

Prof Metra has been principal investigator and member of the Executive or Steering Committees of many trials in patients with heart failure. His research is focused on heart failure with, as main areas of interest, β-blocker therapy and, more recently, the assessment and treatment of the patients with acute heart failure.

He has co-chaired with Prof. Teerlink, San Francisco, CA, the phase IIB Pre-RELAX-AHF and the phase III RELAX-AHF randomized placebo controlled trials in patients with acute heart failure and is chairing the current RELAX-AHF-2 trial, which has as primary end-points the effects of serelaxin on the 180-days mortality and on in-hospital worsening heart…

View full profile